Answers are grounded in this paper and cite their sources.
Objective Neonatal alloimmune thrombocytopenia (NAIT) is a platelet disorder caused by maternal alloimmunization against paternally inherited fetal human platelet antigens (HPA). Here we report a rare case of a Chinese primigravida whose neonate presented with severe NAIT involving concurrent anti-HPA-3a and anti-HPA-5b antibodies. Diagnosis was facilitated by a high-throughput HPA genotyping approach utilizing Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS).Methods A healthy 20-year-old primigravida delivered a full-term female infant with severe thrombocytopenia (platelet count 8 × 109/L) and generalized subcutaneous petechiae; NAIT was suspected, and blood samples were submitted for confirmatory testing. Platelet alloantibody screening was performed using the platelet immunofluorescence test (PIFT). Antibody specificity was determined by enzyme-linked immunosorbent assay (ELISA) and monoclonal antibody specific immobilization of platelet antigens (MAIPA). HPA-1-6w and HPA-15 genotyping was conducted via MALDI-TOF MS.Results Maternal and neonatal plasma were positive for platelet alloantibodies on PIFT. Anti-HPA-5b was detected in maternal plasma by ELISA. MALDI-TOF MS revealed HPA discordance, with the mother typed as HPA-3b/3b, HPA-5a/5a and the neonate as HPA-3a/3b, HPA-5a/5b. MAIPA further confirmed the presence of both anti-HPA-3a and anti-HPA-5b in maternal serum. Based on these laboratory diagnostic findings, the clinicians confirmed a diagnosis of NAIT. Furthermore, the patient was treated with intravenous immunoglobulin (IVIG) and corticosteroids, resulting in significant clinical improvement, and the infant was subsequently discharged in stable condition.Conclusion This case highlights a rare Chinese neonate with NAIT presenting with concurrent anti-HPA-3a and anti-HPA-5b antibodies. This report shows that MALDI-TOF MS-based HPA genotyping is a valuable complement to conventional serological testing. By identifying underlying maternal–neonatal HPA incompatibilities, molecular genotyping helps direct targeted antibody identification and facilitates the diagnostic evaluation of complex NAIT cases involving multiple alloantibodies.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: